Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma with Prior Disease Progression

Irene Y. Cheung,Nai-Kong V. Cheung,Shakeel Modak,Audrey Mauguen,Yi Feng,Ellen M. Basu,Stephen S. Roberts,Govind Ragupathi,Brian H. Kushner

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma with Prior Disease Progression

2020

Irene Y. Cheung
Nai-Kong V. Cheung
Shakeel Modak
Audrey Mauguen
Yi Feng
Ellen M. Basu
Stephen S. Roberts
Govind Ragupathi
Brian H. Kushner

PURPOSEAnti-GD2 monoclonal antibody (mAb) has proven efficacy in high-risk neuroblastoma (HR-NB). A small phase I GD2/GD3 vaccine trial (n = 15) described long-term survival and a favorable safety ...

Keywords:

disease progression
Ganglioside
Oncology
Anti-GD2 Antibody
Monoclonal antibody
high risk neuroblastoma
Internal medicine
Vaccine trial
Neuroblastoma
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations